|
Sep 27
|
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
|
|
Sep 26
|
enVVeno Medical Corporation Announces Proposed Public Offering
|
|
Jun 25
|
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
|
|
Jun 21
|
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
|
|
May 8
|
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 24
|
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
|
|
Apr 16
|
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
|
|
Apr 9
|
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
|
|
Mar 15
|
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
|
|
Mar 6
|
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
|